Cited 0 time in
Corrigendum to “Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer” [604 (2024) 217219 1–12](S0304383524006141)(10.1016/j.canlet.2024.217219)
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chica-Parrado, María Rosario | - |
| dc.contributor.author | Kim, Gun Min | - |
| dc.contributor.author | Uemoto, Yasuaki | - |
| dc.contributor.author | Napolitano, Fabiana | - |
| dc.contributor.author | Lin, Chang-Ching | - |
| dc.contributor.author | Ye, Dan | - |
| dc.contributor.author | Bikorimana, Emmanuel | - |
| dc.contributor.author | Fang, Yisheng | - |
| dc.contributor.author | Lee, Kyung-min | - |
| dc.contributor.author | Mendiratta, Saurabh | - |
| dc.contributor.author | Hanker, Ariella B. | - |
| dc.contributor.author | Arteaga, Carlos L. | - |
| dc.date.accessioned | 2026-02-20T01:30:31Z | - |
| dc.date.available | 2026-02-20T01:30:31Z | - |
| dc.date.issued | 2025-10 | - |
| dc.identifier.issn | 0304-3835 | - |
| dc.identifier.issn | 1872-7980 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/210858 | - |
| dc.description.abstract | The authors regret to report an error in our recently published article by Chica-Parrado et al. titled “Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer,” In this article, cropped images for Western blot loading controls were inadvertently duplicated in several figure panels (Fig. 3A, D, and 6F) during the process of figure preparation. On behalf of all co-authors, we would like to submit a corrigendum to correct these errors. The corrected versions of these 3 figure panels are attached below for your review.[Figure presented][Figure presented][Figure presented] The authors would like to apologise for any inconvenience caused.[Figure presented] | - |
| dc.format.extent | 2 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | ELSEVIER IRELAND LTD | - |
| dc.title | Corrigendum to “Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer” [604 (2024) 217219 1–12](S0304383524006141)(10.1016/j.canlet.2024.217219) | - |
| dc.title.alternative | Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (vol 604, 217219, 2024) | - |
| dc.type | Article | - |
| dc.publisher.location | 아일랜드 | - |
| dc.identifier.doi | 10.1016/j.canlet.2025.217891 | - |
| dc.identifier.scopusid | 2-s2.0-105009953314 | - |
| dc.identifier.wosid | 001569047300001 | - |
| dc.identifier.bibliographicCitation | CANCER LETTERS, v.630, pp 1 - 2 | - |
| dc.citation.title | CANCER LETTERS | - |
| dc.citation.volume | 630 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 2 | - |
| dc.type.docType | Article in press | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.subject.keywordAuthor | Clinical Article | - |
| dc.subject.keywordAuthor | Controlled Study | - |
| dc.subject.keywordAuthor | Erratum | - |
| dc.subject.keywordAuthor | Female | - |
| dc.subject.keywordAuthor | Human | - |
| dc.subject.keywordAuthor | Drug Comparison | - |
| dc.subject.keywordAuthor | Drug Therapy | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0304383525004598?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
